Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin. (February 2019)

• Record Type: Journal Article
• Authors: Rachner, Tilman D; Hofbauer, Lorenz C; Göbel, Andy; Tsourdi, Elena
• Is Part Of: Journal of molecular endocrinology. Volume 62:Number 2(2019)
• Page Start: R145
• Page End: R154
• Publication Date: 2019-02
• Subjects: PTH -- PTH-related protein -- abaloparatide -- sclerostin -- sclerostin antibody -- romosozumab; Molecular endocrinology -- Periodicals; Endocrinology -- Periodicals; 616.407
• DOI: 10.1530/JME-18-0173
• Languages: English
• ISSNs: 0952-5041

Abstract

Abstract : Bone-forming approaches to treat patients with severe osteoporosis are effective, but treatment options are limited, and there is an unmet clinical need for additional drugs. This review discusses two novel and advanced anabolic therapeutic concepts that have successfully completed phase 3 trials. Romosozumab is a monoclonal antibody that targets the Wnt inhibitor sclerostin. Two phase 3 trials (FRAME and ARCH) of romosozumab for the treatment of postmenopausal osteoporosis have been completed. Both trials successfully reached their primary endpoint by reducing vertebral fractures by 75% compared to placebo (FRAME trial) and 48% compared to alendronate (ARCH trial), respectively. Abaloparatide is a PTH-related protein (PTHrP) analog that has displayed bone anabolic activity. In the phase 3 ACTIVE trial, abaloparatide was compared to placebo and teriparatide for 18 months in postmenopausal women who had already experienced an osteoporotic fracture. Abaloparatide successfully reduced the rate of new vertebral fractures by 86% compared to placebo. Furthermore, abaloparatide achieved greater BMD increases at all measured sites compared to both placebo and teriparatide. Based on these results, abaloparatide was FDA approved in April 2017. This review discusses available data of both agents with regard to efficacy and safety as well as their possible future application.